Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Complement component C5a induces aberrant epigenetic modifications in renal tubular epithelial cells accelerating senescence by Wnt4/βcatenin signaling after ischemia/reperfusion injury.

Castellano G, Franzin R, Sallustio F, Stasi A, Banelli B, Romani M, De Palma G, Lucarelli G, Divella C, Battaglia M, Crovace A, Staffieri F, Grandaliano G, Stallone G, Ditonno P, Cravedi P, Cantaluppi V, Gesualdo L.

Aging (Albany NY). 2019 Jul 8;11. doi: 10.18632/aging.102059. [Epub ahead of print]

2.

A Peripheral Blood Gene Expression Signature to Diagnose Subclinical Acute Rejection.

Zhang W, Yi Z, Keung KL, Shang H, Wei C, Cravedi P, Sun Z, Xi C, Woytovich C, Farouk S, Huang W, Banu K, Gallon L, Magee CN, Najafian N, Samaniego M, Djamali A, Alexander SI, Rosales IA, Smith RN, Xiang J, Lerut E, Kuypers D, Naesens M, O'Connell PJ, Colvin R, Menon MC, Murphy B.

J Am Soc Nephrol. 2019 Jul 5. pii: ASN.2018111098. doi: 10.1681/ASN.2018111098. [Epub ahead of print]

PMID:
31278196
3.

Pretransplant transcriptomic signature in peripheral blood predicts early acute rejection.

Zhang W, Yi Z, Wei C, Keung KL, Sun Z, Xi C, Woytovich C, Farouk S, Gallon L, Menon MC, Magee C, Najafian N, Samaniego MD, Djamali A, Alexander SI, Rosales IA, Smith RN, O'Connell PJ, Colvin R, Cravedi P, Murphy B.

JCI Insight. 2019 Jun 6;4(11). pii: 127543. doi: 10.1172/jci.insight.127543. eCollection 2019 Jun 6.

4.

Pretransplant Donor-specific IFNγ ELISPOT as a Predictor of Graft Rejection: A Diagnostic Test Accuracy Meta-analysis.

Montero N, Farouk S, Gandolfini I, Crespo E, Jarque M, Meneghini M, Torija A, Maggiore U, Cravedi P, Bestard O.

Transplant Direct. 2019 Apr 25;5(5):e451. doi: 10.1097/TXD.0000000000000886. eCollection 2019 May.

5.

Criteria for Living Donation from Marginal Donors: One, No One, and One Hundred Thousand.

Cantarelli C, Cravedi P.

Nephron. 2019;142(3):227-232. doi: 10.1159/000500498. Epub 2019 May 20.

6.

Neutrophil Extracellular Traps (NETs) profiles in patients with incident SLE and lupus nephritis.

Bruschi M, Bonanni A, Petretto A, Vaglio A, Pratesi F, Santucci L, Migliorini P, Bertelli R, Galetti M, Belletti S, Cavagna L, Moroni G, Franceschini F, Fredi M, Pazzola G, Allegri L, Sinico RA, Pesce G, Bagnasco M, Manfredi A, Ramirez GA, Ramoino P, Bianchini P, Puppo F, Pupo F, Negrini S, Mattana F, Emmi G, Garibotto G, Santoro D, Scolari F, Ravelli A, Tincani A, Cravedi P, Volpi S, Candiano G, Ghiggeri GM.

J Rheumatol. 2019 May 15. pii: jrheum.181232. doi: 10.3899/jrheum.181232. [Epub ahead of print]

PMID:
31092713
7.

Interleukin-1β-induced IRAK1 ubiquitination is required for TH-GM-CSF cell differentiation in T cell-mediated inflammation.

Hu Y, Xu F, Zhang R, Legarda D, Dai J, Wang D, Li H, Zhang Y, Xue Q, Dong G, Zhang H, Lu C, Mortha A, Liu J, Cravedi P, Ting A, Li L, Qi CF, Pierce S, Merad M, Heeger P, Xiong H.

J Autoimmun. 2019 Aug;102:50-64. doi: 10.1016/j.jaut.2019.04.010. Epub 2019 May 10.

PMID:
31080014
8.

Switching renal transplant recipients to belatacept therapy: results of a real-life gradual conversion protocol.

Malvezzi P, Fischman C, Rigault G, Jacob MC, Raskovalova T, Jouve T, Janbon B, Rostaing L, Cravedi P.

Transpl Immunol. 2019 May 6:101207. doi: 10.1016/j.trim.2019.04.002. [Epub ahead of print]

PMID:
31071442
9.

T-cell exhaustion correlates with improved outcomes in kidney transplant recipients.

Fribourg M, Anderson L, Fischman C, Cantarelli C, Perin L, La Manna G, Rahman A, Burrell BE, Heeger PS, Cravedi P.

Kidney Int. 2019 Feb 27. pii: S0085-2538(19)30192-9. doi: 10.1016/j.kint.2019.01.040. [Epub ahead of print]

PMID:
31040060
10.

Erythropoietin inhibits SGK1-dependent TH17 induction and TH17-dependent kidney disease.

Donadei C, Angeletti A, Cantarelli C, D'Agati VD, La Manna G, Fiaccadori E, Horwitz JK, Xiong H, Guglielmo C, Hartzell S, Madsen JC, Maggiore U, Heeger PS, Cravedi P.

JCI Insight. 2019 Apr 23;5. pii: 127428. doi: 10.1172/jci.insight.127428.

11.

Making Procurement Biopsies Important Again for Kidney Transplant Allocation.

Angeletti A, Cravedi P.

Nephron. 2019;142(1):34-39. doi: 10.1159/000499452. Epub 2019 Apr 1.

12.

Erythropoietin, a multifaceted protein with innate and adaptive immune modulatory activity.

Cantarelli C, Angeletti A, Cravedi P.

Am J Transplant. 2019 Mar 23. doi: 10.1111/ajt.15369. [Epub ahead of print] Review.

PMID:
30903735
13.

Effect of Timing and Complement Receptor Antagonism on Intragraft Recruitment and Protolerogenic Effects of Mesenchymal Stromal Cells in Murine Kidney Transplantation.

Casiraghi F, Todeschini M, Azzollini N, Cravedi P, Cassis P, Solini S, Fiori S, Rota C, Karachi A, Carrara C, Noris M, Perico N, Remuzzi G.

Transplantation. 2019 Jun;103(6):1121-1130. doi: 10.1097/TP.0000000000002611.

PMID:
30801518
14.

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents.

Angeletti A, Cantarelli C, Cravedi P.

Front Med (Lausanne). 2019 Feb 8;6:20. doi: 10.3389/fmed.2019.00020. eCollection 2019. Review.

15.

Editorial: New perspectives to increase transplant numbers and survival.

Cravedi P.

Curr Opin Organ Transplant. 2019 Feb;24(1):1-3. doi: 10.1097/MOT.0000000000000602. No abstract available.

PMID:
30507706
16.

SHROOM3-FYN Interaction Regulates Nephrin Phosphorylation and Affects Albuminuria in Allografts.

Wei C, Banu K, Garzon F, Basgen JM, Philippe N, Yi Z, Liu R, Choudhuri J, Fribourg M, Liu T, Cumpelik A, Wong J, Khan M, Das B, Keung K, Salem F, Campbell KN, Kaufman L, Cravedi P, Zhang W, O'Connell PJ, He JC, Murphy B, Menon MC.

J Am Soc Nephrol. 2018 Nov;29(11):2641-2657. doi: 10.1681/ASN.2018060573. Epub 2018 Oct 19.

PMID:
30341149
17.

A large, international study on post-transplant glomerular diseases: the TANGO project.

Uffing A, Pérez-Sáez MJ, La Manna G, Comai G, Fischman C, Farouk S, Manfro RC, Bauer AC, Lichtenfels B, Mansur JB, Tedesco-Silva H, Kirsztajn GM, Manonelles A, Bestard O, Riella MC, Hokazono SR, Arias-Cabrales C, David-Neto E, Ventura CG, Akalin E, Mohammed O, Khankin EV, Safa K, Malvezzi P, O'Shaughnessy MM, Cheng XS, Cravedi P, Riella LV.

BMC Nephrol. 2018 Sep 12;19(1):229. doi: 10.1186/s12882-018-1025-z.

18.

Impact of preformed T-cell alloreactivity by means of donor-specific and panel of reactive T cells (PRT) ELISPOT in kidney transplantation.

Gandolfini I, Crespo E, Baweja M, Jarque M, Donadei C, Luque S, Montero N, Allesina A, Perin L, Maggiore U, Cravedi P, Bestard O.

PLoS One. 2018 Jul 30;13(7):e0200696. doi: 10.1371/journal.pone.0200696. eCollection 2018.

19.

Rethinking Regenerative Medicine From a Transplant Perspective (and Vice Versa).

Orlando G, Murphy SV, Bussolati B, Clancy M, Cravedi P, Migliaccio G, Murray P.

Transplantation. 2019 Feb;103(2):237-249. doi: 10.1097/TP.0000000000002370.

PMID:
30028414
20.

History of Childhood Kidney Disease and Risk of Adult End-Stage Renal Disease.

Castellano G, Cravedi P.

N Engl J Med. 2018 May 3;378(18):1750. doi: 10.1056/NEJMc1802894. No abstract available.

PMID:
29722515
21.

T Cell Expression of C5a Receptor 2 Augments Murine Regulatory T Cell (TREG) Generation and TREG-Dependent Cardiac Allograft Survival.

A Verghese D, Demir M, Chun N, Fribourg M, Cravedi P, Llaudo I, Woodruff TM, Yadav P, Lira SA, Medof ME, Heeger PS.

J Immunol. 2018 Mar 15;200(6):2186-2198. doi: 10.4049/jimmunol.1701638. Epub 2018 Feb 7.

22.

Rapid Biolayer Interferometry Measurements of Urinary CXCL9 to Detect Cellular Infiltrates Noninvasively After Kidney Transplantation.

Gandolfini I, Harris C, Abecassis M, Anderson L, Bestard O, Comai G, Cravedi P, Cremaschi E, Duty JA, Florman S, Friedewald J, La Manna G, Maggiore U, Moran T, Piotti G, Purroy C, Jarque M, Nair V, Shapiro R, Reid-Adam J, Heeger PS.

Kidney Int Rep. 2017 Jun 21;2(6):1186-1193. doi: 10.1016/j.ekir.2017.06.010. eCollection 2017 Nov.

23.

CD55 Deficiency and Protein-Losing Enteropathy.

Angeletti A, Marasà M, Cravedi P.

N Engl J Med. 2017 Oct 12;377(15):1499. doi: 10.1056/NEJMc1710011. No abstract available.

PMID:
29022673
24.

Analysis of OPTN/UNOS registry suggests the number of HLA matches and not mismatches is a stronger independent predictor of kidney transplant survival.

Yacoub R, Nadkarni GN, Cravedi P, He JC, Delaney VB, Kent R, Chauhan KN, Coca SG, Florman SS, Heeger PS, Murphy B, Menon MC.

Kidney Int. 2018 Feb;93(2):482-490. doi: 10.1016/j.kint.2017.07.016. Epub 2017 Sep 29.

PMID:
28965746
25.

Regenerative immunology: the immunological reaction to biomaterials.

Cravedi P, Farouk S, Angeletti A, Edgar L, Tamburrini R, Duisit J, Perin L, Orlando G.

Transpl Int. 2017 Dec;30(12):1199-1208. doi: 10.1111/tri.13068. Epub 2017 Oct 5. Review.

26.

Complement in Non-Antibody-Mediated Kidney Diseases.

Angeletti A, Reyes-Bahamonde J, Cravedi P, Campbell KN.

Front Med (Lausanne). 2017 Jul 12;4:99. doi: 10.3389/fmed.2017.00099. eCollection 2017. Review.

27.

Looking into the Graft without a Biopsy: Biomarkers of Acute Rejection in Renal Transplantation.

Angeletti A, Cravedi P.

Contrib Nephrol. 2017;190:181-193. doi: 10.1159/000468967. Epub 2017 May 23. Review.

PMID:
28535529
28.

New biologics in the treatment of rare glomerular diseases of childhood.

Cravedi P, Angeletti A, Remuzzi G.

Curr Opin Pharmacol. 2017 Apr;33:27-33. doi: 10.1016/j.coph.2017.03.010. Epub 2017 Apr 26. Review.

PMID:
28456094
29.

Erythropoietin Receptor-Mediated Molecular Crosstalk Promotes T Cell Immunoregulation and Transplant Survival.

Purroy C, Fairchild RL, Tanaka T, Baldwin WM 3rd, Manrique J, Madsen JC, Colvin RB, Alessandrini A, Blazar BR, Fribourg M, Donadei C, Maggiore U, Heeger PS, Cravedi P.

J Am Soc Nephrol. 2017 Aug;28(8):2377-2392. doi: 10.1681/ASN.2016101100. Epub 2017 Mar 16.

30.

Posttransplant peripheral blood donor-specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients.

Crespo E, Cravedi P, Martorell J, Luque S, Melilli E, Cruzado JM, Jarque M, Meneghini M, Manonelles A, Donadei C, Lloberas N, Gomà M, Grinyó JM, Heeger P, Bestard O.

Kidney Int. 2017 Jul;92(1):201-213. doi: 10.1016/j.kint.2016.12.024. Epub 2017 Mar 6.

31.

Rituximab as First-Line Therapy in Severe Lupus Erythematosus with Neuropsychiatric and Renal Involvement: A Case-Report and Review of the Literature.

Angeletti A, Baraldi O, Chiocchini AL, Comai G, Cravedi P, La Manna G.

J Clin Case Rep. 2017;7(10). pii: 1033. doi: 10.4172/2165-7920.10001033. Epub 2017 Oct 27.

32.

Achieving remission of proteinuria in childhood CKD.

Ruggenenti P, Cravedi P, Chianca A, Caruso M, Remuzzi G.

Pediatr Nephrol. 2017 Feb;32(2):321-330. doi: 10.1007/s00467-016-3495-1. Epub 2016 Oct 4.

33.

Rituximab in Membranous Nephropathy: Not All Studies Are Created Equal.

Cravedi P.

Nephron. 2017;135(1):46-50. doi: 10.1159/000450659. Epub 2016 Sep 28. Review.

34.

A step towards clinical application of acellular matrix: A clue from macrophage polarization.

Petrosyan A, Da Sacco S, Tripuraneni N, Kreuser U, Lavarreda-Pearce M, Tamburrini R, De Filippo RE, Orlando G, Cravedi P, Perin L.

Matrix Biol. 2017 Jan;57-58:334-346. doi: 10.1016/j.matbio.2016.08.009. Epub 2016 Aug 26.

PMID:
27575985
35.

Monitoring alloimmune response in kidney transplantation.

Bestard O, Cravedi P.

J Nephrol. 2017 Apr;30(2):187-200. doi: 10.1007/s40620-016-0320-7. Epub 2016 May 31. Review.

36.

ACTH action on podocytes: mystery solved?

Cravedi P, Campbell KN.

Am J Physiol Renal Physiol. 2016 Jun 1;310(11):F1178-9. doi: 10.1152/ajprenal.00139.2016. Epub 2016 Mar 9. No abstract available.

37.

The Human Pancreas as a Source of Protolerogenic Extracellular Matrix Scaffold for a New-generation Bioartificial Endocrine Pancreas.

Peloso A, Urbani L, Cravedi P, Katari R, Maghsoudlou P, Fallas ME, Sordi V, Citro A, Purroy C, Niu G, McQuilling JP, Sittadjody S, Farney AC, Iskandar SS, Zambon JP, Rogers J, Stratta RJ, Opara EC, Piemonti L, Furdui CM, Soker S, De Coppi P, Orlando G.

Ann Surg. 2016 Jul;264(1):169-79. doi: 10.1097/SLA.0000000000001364.

38.

Evolution of the Selenoproteome in Helicobacter pylori and Epsilonproteobacteria.

Cravedi P, Mori G, Fischer F, Percudani R.

Genome Biol Evol. 2015 Sep 4;7(9):2692-704. doi: 10.1093/gbe/evv177.

39.

A multidrug, antiproteinuric approach to alport syndrome: a ten-year cohort study.

Daina E, Cravedi P, Alpa M, Roccatello D, Gamba S, Perna A, Gaspari F, Remuzzi G, Ruggenenti P.

Nephron. 2015;130(1):13-20. doi: 10.1159/000381480. Epub 2015 Apr 21.

40.

Corrigendum. Complement as a multifaceted modulator of kidney transplant injury.

Cravedi P, Heeger PS.

J Clin Invest. 2015 Mar 2;125(3):1365. doi: 10.1172/JCI81182. Epub 2015 Mar 2. No abstract available.

41.

Monitoring T cell alloreactivity.

Mehrotra A, Leventhal J, Purroy C, Cravedi P.

Transplant Rev (Orlando). 2015 Apr;29(2):53-9. doi: 10.1016/j.trre.2014.11.001. Epub 2014 Nov 12. Review.

PMID:
25475045
42.

Rituximab in primary membranous nephropathy: first-line therapy, why not?

Cravedi P, Remuzzi G, Ruggenenti P.

Nephron Clin Pract. 2014;128(3-4):261-9. doi: 10.1159/000368589. Epub 2014 Nov 22. Review.

43.

Refractory focal segmental glomerulosclerosis in the adult: complete and sustained remissions of two episodes of nephrotic syndrome after a single dose of rituximab.

Marasà M, Cravedi P, Ruggiero B, Ruggenenti P.

BMJ Case Rep. 2014 Aug 25;2014. pii: bcr2014205507. doi: 10.1136/bcr-2014-205507.

44.

The Kidney Donor Profile Index (KDPI) of marginal donors allocated by standardized pretransplant donor biopsy assessment: distribution and association with graft outcomes.

Gandolfini I, Buzio C, Zanelli P, Palmisano A, Cremaschi E, Vaglio A, Piotti G, Melfa L, La Manna G, Feliciangeli G, Cappuccilli M, Scolari MP, Capelli I, Panicali L, Baraldi O, Stefoni S, Buscaroli A, Ridolfi L, D'Errico A, Cappelli G, Bonucchi D, Rubbiani E, Albertazzi A, Mehrotra A, Cravedi P, Maggiore U.

Am J Transplant. 2014 Nov;14(11):2515-25. doi: 10.1111/ajt.12928. Epub 2014 Aug 25.

45.

The marginal kidney donor.

Maggiore U, Cravedi P.

Curr Opin Organ Transplant. 2014 Aug;19(4):372-80. doi: 10.1097/MOT.0000000000000081. Review.

PMID:
24977323
46.

Complement as a multifaceted modulator of kidney transplant injury.

Cravedi P, Heeger PS.

J Clin Invest. 2014 Jun;124(6):2348-54. doi: 10.1172/JCI72273. Epub 2014 Jun 2. Review. Erratum in: J Clin Invest. 2015 Mar 2;125(3):1365.

47.

Role of monoclonal antibodies in the treatment of immune-mediated glomerular diseases.

Manrique J, Cravedi P.

Nefrologia. 2014 May 21;34(3):388-97. doi: 10.3265/Nefrologia.pre2014.Feb.12506. Epub 2014 Apr 10. Review. English, Spanish.

48.

Immunosuppressive effects of erythropoietin on human alloreactive T cells.

Cravedi P, Manrique J, Hanlon KE, Reid-Adam J, Brody J, Prathuangsuk P, Mehrotra A, Heeger PS.

J Am Soc Nephrol. 2014 Sep;25(9):2003-15. doi: 10.1681/ASN.2013090945. Epub 2014 Mar 27.

49.

Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome.

Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Marasà M, Chianca A, Rubis N, Ene-Iordache B, Rudnicki M, Pollastro RM, Capasso G, Pisani A, Pennesi M, Emma F, Remuzzi G; Rituximab in Nephrotic Syndrome of Steroid-Dependent or Frequently Relapsing Minimal Change Disease Or Focal Segmental Glomerulosclerosis (NEMO) Study Group.

J Am Soc Nephrol. 2014 Apr;25(4):850-63. doi: 10.1681/ASN.2013030251. Epub 2014 Jan 30.

50.

The Impact of Histologic Variants on FSGS Outcomes.

Meliambro K, Schwartzman M, Cravedi P, Campbell KN.

Int Sch Res Notices. 2014 Oct 29;2014:913690. doi: 10.1155/2014/913690. eCollection 2014. Review.

Supplemental Content

Loading ...
Support Center